Table 3.
Clinical outcome between PCP and non-PCP patients with positive Pneumocystis jirovecii polymerase chain reaction
| Variable | PCP (n = 90) | Non-PCP (n = 79) | p value |
|---|---|---|---|
| Improved | 56 (62) | 66a (84) | 0.002 |
| Death | 34 (38) | 13 (16) | |
| Cause of death | |||
| ARDS | 12/34 | 3/13 | |
| Sepsis | 5/34 | 2/13 | |
| Multiorgan failure | 12/34 | 5/13 | |
| Cardiac arrest | 3/34 | 3/13 | |
| Death related to PCP | 2 (2) | 0 |
Values are presented as number (%).
PCP, Pneumocystis pneumonia; ARDS, acute respiratory distress syndrome.
a
Improvement in the non-PCP group (n = 66) is due to the following; supportive care (6/66), antibiotics (48/66), anti-tuberculosis medication (3/66), anti-fungal (1/66), others (steroid, tamiflu, etc.; 8/66).